Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.

BACKGROUND Monitoring the immune response to epitope-specific vaccination in cancer patients is important for vaccine development. The traditional method, in which the in vitro sensitization of peripheral blood mononuclear cells (PBMCs) with epitope is compared before and after vaccination, is time-consuming and allows only a qualitative assessment of the response. We used a rapid, quantitative, real-time polymerase chain reaction (PCR) assay to directly measure the immune reactivity of patients' PBMCs to the vaccine epitope. METHODS PBMCs were obtained from melanoma patients before and after two rounds of vaccination with either g209-2M, a peptide derived from melanoma protein gp100 (n = 24), or ESg209-2M, a modified version of this peptide (n = 20). PBMCs were tested for immune reactivity by assaying interferon gamma (IFN gamma) protein release after in vitro sensitization with the epitope or for IFN gamma messenger RNA expression by real-time PCR. A twofold or more increase in IFN gamma protein release or a 1.5-fold or more increase in IFN gamma transcript accumulation in PBMCs after vaccination was considered to be evidence of a specific response. Correlation between the two methods was tested by use of the Spearman correlation coefficient after the results were ranked as positive or negative. All statistical tests were two-sided. RESULTS The results obtained with the two methods were strongly correlated (Spearman's rho = 0.72; P =.0006). The g209-2M and Esg209-2M peptides resulted in similar percentages of vaccine-specific reactivity in PBMCs after in vitro sensitization (63% and 65% of patients, respectively; Fisher's exact test P =.6 for comparison of the two groups). The PCR method could detect vaccine-specific reactivity in a subset of patients (38% and 35% of patients, respectively; Fisher's exact test P =.7 for comparison of the two groups). CONCLUSION Vaccination induces circulating antitumor lymphocytes, albeit in low frequencies, capable of directly reacting with tumor antigen. PBMCs of vaccinated individuals can respond to a vaccine-specific stimulus in a direct assay that does not require prolonged in vitro manipulations.

[1]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[2]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[3]  S. Rowland-Jones,et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.

[4]  S. Rosenberg,et al.  Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. , 1998, The cancer journal from Scientific American.

[5]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[6]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[7]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[8]  P. Rieckmann,et al.  Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. , 1997, Journal of immunological methods.

[9]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay , 1997 .

[10]  S. Rosenberg.  Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[11]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[12]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. , 1997, International journal of cancer.

[13]  S. Rosenberg.  Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.

[14]  J. Cormier,et al.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.

[15]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[16]  K. Livak,et al.  Real time quantitative PCR. , 1996, Genome research.

[17]  F. Marincola,et al.  Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[18]  M. Salgaller,et al.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[19]  S. Kurtzman,et al.  Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. , 1996, Cancer research.

[20]  M. Salgaller,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. , 1995, Cancer research.

[21]  A Sette,et al.  Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.

[22]  S. Rosenberg,et al.  Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. , 1994, Cancer research.

[23]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[25]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Maria L. Wei,et al.  HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides , 1992, Nature.